AMBS logo

Amarantus BioScience Holdings Inc



Closed: 29 Feb 2024 21:00 US/Eastern

Key details






null, null




Pharmaceutical Preparation Manufacturing

About Amarantus BioScience Holdings Inc

amarantus bioscience holdings (otcqb: ambs) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. ambs owns the rights to engineered skin substitute program, a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ess is entering phase 2 clinical studies under a crada agreement with the us army, and is also preparing a pivotal development program for rare pediatric disease giant congenital melanocytic nevi. ambs' also has licensing rights to eltoprazine, a phase 2b-ready small molecule indicated for parkinson's disease levodopa-induced dyskinesia, adult adhd and alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor and is developing manf-based products as treatments for brain and ophthalmic disorders. ambs' diagnostics division

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG